Regeneron Q3 revenue rises 11% to $3.72 billion; GAAP EPS up 30% to $11.54
Regeneron reported third quarter 2024 revenue of $3.72 billion, up 11% from a year earlier, and GAAP diluted earnings per share of $11.54, up 30%. Non-GAAP diluted EPS rose 8% to $12.46, and the company cut the top end of its non-GAAP SG&A guidance while raising its capital expenditure guidance.
Key points
- Total revenues rose 11% to $3.72 billion; GAAP net income rose 33% to $1.34 billion.
- Non-GAAP diluted EPS rose 8% to $12.46, including an unfavorable $0.43 impact from acquired IPR&D charges.
- Repurchased $738 million of stock in the quarter; $2.9 billion remained under the buyback program at September 30, 2024.
- Full-year 2024 capital expenditure guidance was raised to $750–$820 million from $700–$740 million.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 31, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.